This is the authors' abstract. We don't add key points for this paper.
Summary This study reports the relationship between CD38+ regulatory T cells (Tregs) and messenger RNA coronavirus disease 2019 (mRNA‐COVID‐19) vaccination in 60 patients with plasma cell dyscrasia. Patients treated with anti‐CD38 monoclonal antibodies (mAbs) had significantly lower CD38+ Tregs than those not treated (0.9 vs. 13.2/μl). Late‐responders, whose antibody titres increased from weeks 4–12 after the second vaccination, had significantly lower CD38+ Treg counts than non‐late‐responders (2.5 vs. 10.3/μl). Antibody titres in patients with lower CD38+ Treg levels were maintained from weeks 4–12 but decreased in those with higher CD38+ Treg levels. Therefore, depletion of CD38+ Tregs by anti‐CD38 mAbs may induce a durable response to mRNA‐COVID‐19 vaccination.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Terao et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: